Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

Abstract Background Intratumor subsets with tumor-initiating features in glioblastoma are likely to survive treatment. Our goal is to identify the key factor in the process by which cells develop temozolomide (TMZ) resistance. Methods Resistant cell lines derived from U87MG and A172 were established...

Full description

Bibliographic Details
Main Authors: Chia-Hung Chien, Jian-Ying Chuang, Shun-Tai Yang, Wen-Bin Yang, Pin-Yuan Chen, Tsung-I Hsu, Chih-Yuan Huang, Wei-Lun Lo, Ka-Yen Yang, Ming-Sheng Liu, Jui-Mei Chu, Pei-Hsuan Chung, Jr-Jiun Liu, Shao-Wen Chou, Shang-Hung Chen, Kwang-Yu Chang
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Biomedical Science
Subjects:
SOD2
ROS
Glioblastoma
Tumor-initiating cells
Temozolomide
Online Access:http://link.springer.com/article/10.1186/s12929-019-0565-2

Internet

http://link.springer.com/article/10.1186/s12929-019-0565-2

Similar Items